Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2020-10-22 | Odysseas D. Kostas, M.D. has served as a member of our Board of Directors since February 2020. ... Dr. Kostas is a member of the Nominating and Corporate Governance Committee. ... No compensation details were provided for Dr. Kostas in the filing. |
| 2021-02-26 | Dr. Kostas, who recused themselves from the Board’s approval of the Private Placement. Dr. Kostas is affiliated with Innoviva and is expected to continue as a member of the Board following the closing of the Private Placement. |
| 2021-04-21 | Odysseas D. Kostas, M.D. has served as a member of our Board of Directors since February 2020. ... Mr. Kostas was selected as a director because of his extensive leadership experience with biotechnology companies and his in-depth knowledge of our business, strategy and management team, as well as his experience serving as a public company director. |
| 2022-03-09 | As of the date of this Agreement, Dr. Odysseas Kostas MD and Jules Haimovitz are the Investor Designees. |
| 2022-10-17 | Odysseas D. Kostas, M.D. has served as a member of our board of directors since February 2020. He also currently serves as a director of Innoviva, Inc. He is a Partner and Senior Managing Director at Sarissa Capital Management LP. Sarissa Capital focuses on improving the strategies of companies to enhance shareholder value. Prior to joining Sarissa Capital, Dr. Kostas served as a Director at Evercore ISI (formerly ISI), covering the biotechnology and pharmaceutical industries. Previously, he practiced internal medicine as part of the Yale New Haven Health System and was engaged as a consultant to various biotechnology companies. Dr. Kostas also previously served on the board of directors of Enzon Pharmaceuticals. Dr. Kostas has a B.S from Massachusetts Institute of Technology (MIT) and a M.D. from University of Texas Southwestern Medical School. Dr. Kostas has demonstrated leadership in his field, and his knowledge of and experience in our industry contributed to our conclusion that he should serve as a director. |
| 2023-08-03 | Odysseas D. Kostas, M.D. has served as a member of our board of directors since February 2020. He also currently serves as a director of Innoviva, Inc. and director/Chairman of Amarin Corporation. He is a Partner and Senior Managing Director at Sarissa Capital Management LP. Sarissa Capital focuses on improving the strategies of companies to enhance shareholder value. |
| 2024-04-29 | Odysseas D. Kostas, M.D. has served as a member of our board of directors since February 2020. He also currently serves as a director of Innoviva, Inc. and director/Chairman of Amarin Corporation. He is a Partner and Senior Managing Director at Sarissa Capital Management LP. |
| Filing Date | Source Excerpt |
|---|---|
| 2018-03-23 | Odysseas D. Kostas, M.D. has served as a member of our Board of Directors since December 2017 and is currently a member of the Compensation Committee of the Board of Directors (the "Compensation Committee") and the Nominating/Corporate Governance Committee of the Board of Directors (the "Nominating/Corporate Governance Committee"). He is a Partner and Senior Analyst at Sarissa Capital Management LP. Sarissa Capital focuses on improving the strategies of companies to enhance shareholder value. Prior to joining Sarissa Capital, Dr. Kostas served as a Director at Evercore ISI (formerly ISI), covering the biotechnology and pharmaceutical industries. Previously, he practiced internal medicine as part of the Yale New Haven Health System and was engaged as a consultant to various biotechnology companies. Dr. Kostas has a B.S from Massachusetts Institute of Technology (MIT) and a M.D. from University of Texas Southwestern Medical School. |
| 2019-03-13 | Dr. Kostas has a B.S from Massachusetts Institute of Technology (MIT) and a M.D. from University of Texas Southwestern Medical School. He practiced internal medicine and was engaged as a consultant to biotechnology companies. |
| 2020-03-11 | Dr. Kostas holds a BS from MIT and an M.D. from University of Texas Southwestern Medical School, with experience in biotech investment and medicine. |
| 2021-04-02 | Dr. Kostas holds a BS from Massachusetts Institute of Technology (MIT) and a M.D. from University of Texas Southwestern Medical School. Dr. Kostas has demonstrated leadership in his field, his knowledge of our industry and experience in our industry contributed to our conclusion that he should serve as a director. |
| 2022-03-25 | Dr. Kostas holds a BS from Massachusetts Institute of Technology (MIT) and a M.D. from University of Texas Southwestern Medical School. |
| 2023-04-28 | Dr. Kostas holds a BS from Massachusetts Institute of Technology (MIT) and a M.D. from University of Texas Southwestern Medical School. Dr. Kostas has demonstrated leadership in his field, his knowledge of our industry and experience in our industry contributed to our conclusion that he should serve as a director. |
| 2024-04-29 | Dr. Kostas holds a BS from Massachusetts Institute of Technology (MIT) and a M.D. from University of Texas Southwestern Medical School. Dr. Kostas has demonstrated leadership in his field, his knowledge of our industry and experience in our industry contributed to our conclusion that he should serve as a director. |
Data sourced from SEC filings. Last updated: 2026-02-03